PDEX Q3 Sales Up 15% to $19.9M, Operating Income Dips 15%; Net Income Surges on $2.3M One-Time Gain
PDEX has more than doubled off its 52-week low of $23.47.
Summary
Pro-Dex, Inc. reported mixed fiscal third-quarter 2026 results, with net sales increasing 15% to $19.9 million, driven by shipments of its next-generation orthopedic handpiece. However, gross margin compressed by 2 percentage points to 31%, and operating income declined 15% to $3.1 million due to unfavorable product mix and higher operating expenses, including acquisition-related costs. Net income surged to $3.9 million, or $1.20 per diluted share, significantly boosted by a $2.3 million realized gain from contingent value rights in Monogram Technologies. This follows a strong Q2, where the company also benefited from Monogram-related cash. While top-line growth is positive, the decline in operational profitability for the quarter, offset by a substantial non-recurring gain, presents a complex picture for investors. Traders will focus on the sustainability of sales growth and the company's ability to improve margins and operating income in future periods without one-time benefits.
At the time of this announcement, PDEX was trading at $50.14 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $160.7M. The 52-week trading range was $23.47 to $68.33. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Access Newswire.